SEC Form 4
Becton, Dickinson and Co. (BDX) insider trading
In the 12 months to Nov 5, 2026, 5 BDX insiders reported open-market sales of $2.8M across 21 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.8M
- 21 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 18 of 21
- $2.1M of $2.8M sold (77%)
Who traded BDX, and when
- Sale
- Sale, pre-arranged (10b5-1)
BDX daily close from Nov 5, 2025 to Nov 5, 2026, between $140.71 and $212.10, last $212.10. 21 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Thomas E. Polen Jr., Chairman, CEO and President: sold $1.2M across 2 filings, first filed Jun 3, 2026, last Aug 14, 2026. Michael David Garrison, EVP & Pres Med.Essntl&BioPharm: sold $784.2K across 4 filings, first filed Dec 17, 2025, last Jun 25, 2026. Roland Goette, EVP and President, EMEA: sold $440.9K across 1 filing, first filed Aug 12, 2026, last Aug 12, 2026. Bertram L. Scott, Director: sold $212.3K across 2 filings, first filed Nov 7, 2025, last Feb 18, 2026. Michael Feld, EVP, CRO & Pres. Life Sciences → EVP, Chief Revenue Officer: sold $175.3K across 12 filings, first filed Dec 2, 2025, last Oct 27, 2026.
Largest mark · tap a row for others
Thomas E. Polen Jr. · Chairman, CEO and President
Sale $768,120
4,152 shares at $185.00 avg
Filed Aug 14, 2026 · traded Aug 13
Pre-arranged (10b5-1) · close on filing date $183.40
Thomas E. Polen Jr. · Chairman, CEO and President
Chairman, CEO and President
$1.2M soldMichael David Garrison · EVP & Pres Med.Essntl&BioPharm
EVP & Pres Med.Essntl&BioPharm
$784.2K soldRoland Goette · EVP and President, EMEA
EVP and President, EMEA
$440.9K soldBertram L. Scott · Director
Director
$212.3K soldMichael Feld · EVP, CRO & Pres. Life Sciences → EVP, Chief Revenue Officer
EVP, CRO & Pres. Life Sciences → EVP, Chief Revenue Officer
$175.3K soldOpen-market trades
21 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Thomas E. Polen Jr. | Chairman, CEO and President | $1.2M | — | 2 | 100% of sales | |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | $784.2K | — | 4 | 100% of sales | |
| Roland Goette | EVP and President, EMEA | $440.9K | — | 1 | — | |
| Bertram L. Scott | Director | $212.3K | — | 2 | — | |
| Michael Feld | EVP, CRO & Pres. Life Sciences → EVP, Chief Revenue Officer | $175.3K | — | 12 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 76 | $198.13 | $15.1K | 19,568 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 76 | $183.70 | $14.0K | 19,644 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 165 | $188.49 | $31.1K | 19,720 | |
traded | Thomas E. Polen Jr. Chairman, CEO and President | SalePre-arranged (10b5-1) | 4,152 | $185.00 | $768.1K | 110,163 | |
traded | Roland Goette EVP and President, EMEA | Sale | 2,438 | $180.84 | $440.9K | 14,856 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 75 | $157.13 | $11.8K | 20,934 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 75 | $152.80 | $11.5K | 21,009 | |
traded | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | SalePre-arranged (10b5-1) | 1,100 | $145.66 | $160.2K | 13,172 | |
traded | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | SalePre-arranged (10b5-1) | 1,100 | $151.48 | $166.6K | 14,272 | |
traded | Thomas E. Polen Jr. Chairman, CEO and President | SalePre-arranged (10b5-1) | 2,764 | $146.35 | $404.5K | 110,163 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 75 | $147.35 | $11.1K | 21,084 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 74 | $151.94 | $11.2K | 21,159 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 75 | $156.83 | $11.8K | 21,233 | |
traded | Michael Feld EVP, Chief Revenue Officer | SalePre-arranged (10b5-1) | 75 | $181.84 | $13.6K | 21,308 | |
traded | Bertram L. Scott Director | Sale | 953 | $182.61 | $174.0K | 36,763 | |
traded | Michael Feld EVP, CRO & Pres. Life Sciences | SalePre-arranged (10b5-1) | 75 | $202.73 | $15.2K | 16,431 | |
traded | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | SalePre-arranged (10b5-1) | 1,610 | $207.46 | $334.0K | 12,095 | |
traded | Michael Feld EVP, CRO & Pres. Life Sciences | SalePre-arranged (10b5-1) | 74 | $196.08 | $14.5K | 16,506 | |
traded | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | SalePre-arranged (10b5-1) | 629 | $196.03 | $123.3K | 13,105 | |
traded | Michael Feld EVP, CRO & Pres. Life Sciences | SalePre-arranged (10b5-1) | 75 | $193.36 | $14.5K | 16,580 | |
traded | Bertram L. Scott Director | Sale | 217 | $176.58 | $38.3K | 35,816 |
GET /stocks/filings/vX/form-4?tickers=BDX&filing_date.gte=2025-11-05&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BDX"
],
"issuer_cik": "0000010795",
"owner_cik": "0002034349",
"accession_number": "0001628280-26-067525",
"form_type": "4",
"filing_date": "2026-10-27",
"period_of_report": "2026-10-26",
"issuer_name": "BECTON DICKINSON & CO",
"issuer_trading_symbol": "BDX",
"owner_name": "Feld Michael",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Chief Revenue Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-26",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 76,
"transaction_price_per_share": 198.13,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 19568,
"transaction_value": 15057.88,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"remarks": "This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026."
},
{
"tickers": [
"BDX"
],
"issuer_cik": "0000010795",
"owner_cik": "0002034349",
"accession_number": "0001628280-26-063882",
"form_type": "4",
"filing_date": "2026-09-29",
"period_of_report": "2026-09-28",
"issuer_name": "BECTON DICKINSON & CO",
"issuer_trading_symbol": "BDX",
"owner_name": "Feld Michael",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Chief Revenue Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-28",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 76,
"transaction_price_per_share": 183.7,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 19644,
"transaction_value": 13961.199999999999,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"remarks": "This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 27, 2026."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 56 records
- Option exercises3 records
- Tax withholding14 records
- Grants and awards36 records
- Other3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Becton, Dickinson and Co.'s CEO sold stock?
Yes. Thomas E. Polen Jr. (CEO) sold 6,916 shares ($1.2M) between Jun 2026 and Aug 2026, all under a pre-arranged 10b5-1 plan.
How current is BDX’s insider data?
These are BDX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BDX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BDX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.